pptx
... The following are signs that a supplement product might be less effective than claimed, or even outright fraudulent: 1. Real science is exaggerated. You need carnitine to burn fat… but you don’t need to take it as a supplement. The body makes it! 2. Claims to treat everything. A vague statement abou ...
... The following are signs that a supplement product might be less effective than claimed, or even outright fraudulent: 1. Real science is exaggerated. You need carnitine to burn fat… but you don’t need to take it as a supplement. The body makes it! 2. Claims to treat everything. A vague statement abou ...
BERBERIS ARISTATA TETRACHLORIDE INDUCED HEPATOTOXICITY IN RATS
... Materials and Methods: Twenty four Wistar albino rats of either sex, weighing 150-200g were procured from Central Animal House of J. N. Medical College, A.M.U. Aligarh. Ethanolic extract of Berberis aristata was prepared with the help of Soxhlet’s apparatus. Rats were divided into four groups of 6 a ...
... Materials and Methods: Twenty four Wistar albino rats of either sex, weighing 150-200g were procured from Central Animal House of J. N. Medical College, A.M.U. Aligarh. Ethanolic extract of Berberis aristata was prepared with the help of Soxhlet’s apparatus. Rats were divided into four groups of 6 a ...
File - Developing Anaesthesia
... RIVAROXABAN Introduction Rivaroxaban (trade name in Australia “Xarelto”), is a drug from a novel class of noncoumarin anticoagulants, (loosely known as NOACs or “New Oral Anticoagulants”) which is an orally active direct Factor Xa inhibitor. It offers some significant therapeutic advantages over war ...
... RIVAROXABAN Introduction Rivaroxaban (trade name in Australia “Xarelto”), is a drug from a novel class of noncoumarin anticoagulants, (loosely known as NOACs or “New Oral Anticoagulants”) which is an orally active direct Factor Xa inhibitor. It offers some significant therapeutic advantages over war ...
- ePrints Soton
... patients and observations by the study investigators or spontaneous reports by patients. Medically qualified personnel were responsible for ensuring that TEAEs were coded using the lowest level term according to the Medical Dictionary for Regulatory Activities (MedDRA), Version 14.1. Investigators w ...
... patients and observations by the study investigators or spontaneous reports by patients. Medically qualified personnel were responsible for ensuring that TEAEs were coded using the lowest level term according to the Medical Dictionary for Regulatory Activities (MedDRA), Version 14.1. Investigators w ...
Studies
... health educators or physicians would train heroin injectors, individually or in injecting partnership pairs, to treat peers with naloxone in case of overdose. Injectors would also be trained in other resuscitation techniques, particularly rescue breathing and, if feasible, CPR. Injectors would be ad ...
... health educators or physicians would train heroin injectors, individually or in injecting partnership pairs, to treat peers with naloxone in case of overdose. Injectors would also be trained in other resuscitation techniques, particularly rescue breathing and, if feasible, CPR. Injectors would be ad ...
PredniSONE Tablets USP, 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and
... function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Growth and development of infant ...
... function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Growth and development of infant ...
Prescribing Information
... reflect exposure to ALVESCO in doses ranging from 80 mcg to 640 mcg twice daily in five double-blind placebo-controlled clinical trials. Studies with once daily dosing are omitted from the safety database because the doses studied once daily are lower than the highest recommended twice daily doses. ...
... reflect exposure to ALVESCO in doses ranging from 80 mcg to 640 mcg twice daily in five double-blind placebo-controlled clinical trials. Studies with once daily dosing are omitted from the safety database because the doses studied once daily are lower than the highest recommended twice daily doses. ...
GP at 6 months in between specialist reviews
... Lisdexamfetamine is licensed for use as a second line agent to methylphenidate. This should preferably be done after the use of at least two modified release preparations of methylphenidate unless a previous adverse reaction to methylphenidate or unacceptable side effect has ruled out further use. I ...
... Lisdexamfetamine is licensed for use as a second line agent to methylphenidate. This should preferably be done after the use of at least two modified release preparations of methylphenidate unless a previous adverse reaction to methylphenidate or unacceptable side effect has ruled out further use. I ...
Modified thromboelastography evaluation of platelet dysfunction in
... The study was approved by the Institutional Human Research Review Committee and registered at the ClinicalTrials.gov website (Identifier NCT00778492). Given the noninterventional nature of the study, the Institutional Human Research Review Committee waived the need to obtain written consent from the ...
... The study was approved by the Institutional Human Research Review Committee and registered at the ClinicalTrials.gov website (Identifier NCT00778492). Given the noninterventional nature of the study, the Institutional Human Research Review Committee waived the need to obtain written consent from the ...
PENTAZOCINE VERSUS PENTAZOCINE WITH RECTAL DICLOFENAC FOR POSTOPERATIVE PAIN
... Inadequate analgesia has been found to reduce patients’ satisfaction22 and may cause unwanted physiologic and psychological effects23. In a preliminary study by Pinto Pereira et al24, patients in the diclofenac suppository group were discharged earlier than the patients in the intramuscular diclofen ...
... Inadequate analgesia has been found to reduce patients’ satisfaction22 and may cause unwanted physiologic and psychological effects23. In a preliminary study by Pinto Pereira et al24, patients in the diclofenac suppository group were discharged earlier than the patients in the intramuscular diclofen ...
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical
... There are currently two main types of NOACs: direct thrombin inhibitors (ie, dabigatran) and factor Xa inhibitors (ie, rivaroxaban, apixaban). Unlike warfarin, NOACs inhibit a single coagulation factor, have short half-lives and do not require either monitoring or dose titration. Dabigatran etexilat ...
... There are currently two main types of NOACs: direct thrombin inhibitors (ie, dabigatran) and factor Xa inhibitors (ie, rivaroxaban, apixaban). Unlike warfarin, NOACs inhibit a single coagulation factor, have short half-lives and do not require either monitoring or dose titration. Dabigatran etexilat ...
A Randomised, Double Blind Trial of N- Stapes Surgery
... Minor but significant effects were observed in one of these trials [21], but the effect of antioxidants on permanent threshold shifts have not been examined. We performed a clinical trial to determine if N-Acetylcysteine can improve high-frequency hearing (6 and 8 kHz) after stapedotomy. Patients we ...
... Minor but significant effects were observed in one of these trials [21], but the effect of antioxidants on permanent threshold shifts have not been examined. We performed a clinical trial to determine if N-Acetylcysteine can improve high-frequency hearing (6 and 8 kHz) after stapedotomy. Patients we ...
Original Article Inhibitory effects of 19 antiprotozoal drugs and
... WR238605 was superior to the other drugs because the blood from the hamsters treated with it failed to develop parasitemia six weeks after subinoculation, indicating that a parasitological cure had been achieved. The subpassage of blood was taken as the preferred method to assess drug activity. WR23 ...
... WR238605 was superior to the other drugs because the blood from the hamsters treated with it failed to develop parasitemia six weeks after subinoculation, indicating that a parasitological cure had been achieved. The subpassage of blood was taken as the preferred method to assess drug activity. WR23 ...
061799 Gastrointestinal Toxicity of Nonsteroidal
... at least 10 to 20 percent of patients have dyspepsia while taking an NSAID, although the prevalence may range from 5 to 50 percent.10,11 Within a sixmonth period of treatment, 5 to 15 percent of patients with rheumatoid arthritis can be expected to discontinue NSAID therapy because of dyspepsia.11 A ...
... at least 10 to 20 percent of patients have dyspepsia while taking an NSAID, although the prevalence may range from 5 to 50 percent.10,11 Within a sixmonth period of treatment, 5 to 15 percent of patients with rheumatoid arthritis can be expected to discontinue NSAID therapy because of dyspepsia.11 A ...
Asthma
... controller drug for the (off label) treatment of asthma or COPD (approved) • Use a spacer and avoid getting spray in the eyes • Be prepared to increase dose if necessary from 2-3 puffs 3-4 times per day to 6-8 puffs 3-4 times per day, if tolerated • Caution patients that the onset of effect is slow; ...
... controller drug for the (off label) treatment of asthma or COPD (approved) • Use a spacer and avoid getting spray in the eyes • Be prepared to increase dose if necessary from 2-3 puffs 3-4 times per day to 6-8 puffs 3-4 times per day, if tolerated • Caution patients that the onset of effect is slow; ...
2 MB - opioids_
... • Its high affinity and selectivity for μ opioid receptors have made it a common probe for μ effects in pharmacologic studies. ...
... • Its high affinity and selectivity for μ opioid receptors have made it a common probe for μ effects in pharmacologic studies. ...
Fungal nail infection: Assessing the new treatment options W ■
... the treatment of onychomycosis, is an allylamine with fungicidal activity capable of eradicating onychomycosis. It is indicated for dermatophyte infections. It has relatively poor efficacy against Candida and nondermatophyte molds. In studies comparing terbinafine with itraconazole for T rubrum infe ...
... the treatment of onychomycosis, is an allylamine with fungicidal activity capable of eradicating onychomycosis. It is indicated for dermatophyte infections. It has relatively poor efficacy against Candida and nondermatophyte molds. In studies comparing terbinafine with itraconazole for T rubrum infe ...
HERBAL TREATMENT FOR URINARY STONES
... by laters disintegration and flush out of disintegrated partical with the flow of urine. Cystone relaxes the detrusor muscles and promotes diuretics by virtue of its high content of natural mineral salts. Cystone has also been found to be useful in urolithiasis, crystalluria, and urinary tract infec ...
... by laters disintegration and flush out of disintegrated partical with the flow of urine. Cystone relaxes the detrusor muscles and promotes diuretics by virtue of its high content of natural mineral salts. Cystone has also been found to be useful in urolithiasis, crystalluria, and urinary tract infec ...
Protecting Public Health from Outside the Physician`s Office: A
... distinct and complementary roles: the physician as healer, the public sector regulator as protector, and the private sector investor as innovator. Physicians, as licensed health care practitioners, are professionally obliged to serve and protect the best interests of their patients. Medical ethics d ...
... distinct and complementary roles: the physician as healer, the public sector regulator as protector, and the private sector investor as innovator. Physicians, as licensed health care practitioners, are professionally obliged to serve and protect the best interests of their patients. Medical ethics d ...
Non-IOP-Lowering and Unconventional IOP
... systemic hypotension. In one long-term study, all subjects undergoing a trial of marijuana to lower IOP eventually abandoned its use. Attempts to deliver the drug through other routes and thus to bypass effects on the central nervous system have so far been mostly unsuccessful. While a topical deliv ...
... systemic hypotension. In one long-term study, all subjects undergoing a trial of marijuana to lower IOP eventually abandoned its use. Attempts to deliver the drug through other routes and thus to bypass effects on the central nervous system have so far been mostly unsuccessful. While a topical deliv ...
Windtree Therapeutics (WINT)
... prematurely, and most estimates of incidence indicate that around 10% of these develop RDS. However, many infants who are at risk for RDS also receive surfactant therapy prophylactically. We therefore estimate that 3%, or 120,000 newborns per year are candidates for surfactant therapy in the US. As ...
... prematurely, and most estimates of incidence indicate that around 10% of these develop RDS. However, many infants who are at risk for RDS also receive surfactant therapy prophylactically. We therefore estimate that 3%, or 120,000 newborns per year are candidates for surfactant therapy in the US. As ...
Nasacort AQ (troamcinolone acetonide)
... Recommended Dose and Dosage Adjustment Adults and children 12 years of age and older: The recommended starting dose of NASACORT AQ (triamcinolone acetonide aqueous nasal spray) is 220 mcg as two sprays in each nostril once daily. It is always desirable to titrate an individual patient to the minimum ...
... Recommended Dose and Dosage Adjustment Adults and children 12 years of age and older: The recommended starting dose of NASACORT AQ (triamcinolone acetonide aqueous nasal spray) is 220 mcg as two sprays in each nostril once daily. It is always desirable to titrate an individual patient to the minimum ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.